Akinzeo, manufactured by Helsinn, is a combination medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It contains the active ingredients netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, and palonosetron is a serotonin-5-HT3 receptor antagonist [1].
How do netupitant and palonosetron work together?
The two active ingredients in Akinzeo target different pathways involved in nausea and vomiting. Netupitant blocks the NK1 receptor, which plays a role in the delayed phase of CINV. Palonosetron blocks the 5-HT3 receptor, which is primarily involved in the acute phase of CINV [1]. This dual mechanism aims to provide comprehensive protection against both immediate and later-onset nausea and vomiting caused by chemotherapy [1].
When was Akinzeo approved?
Akinzeo received marketing authorization from the European Medicines Agency (EMA) in October 2015 [2]. In the United States, the FDA approved a similar fixed-dose combination of netupitant and palonosetron under the brand name Akynzeo, manufactured by Eisai, in 2015 [3].
What is the typical dosage and administration of Akinzeo?
Akinzeo is typically administered as a single oral dose approximately one hour before the start of chemotherapy [1]. The specific dosage and administration may vary based on the type of chemotherapy regimen and individual patient factors.
Are there any potential side effects associated with Akinzeo?
Common side effects reported with Akinzeo include headache, fatigue, and constipation [4]. More serious side effects are rare but can occur. Patients should discuss potential risks and benefits with their healthcare provider [4].
What are the patent details for Helsinn's Akinzeo?
Information regarding specific patent expiry dates for Helsinn's Akinzeo is available through specialized drug patent databases [5]. Patent protection for pharmaceuticals is complex and can involve multiple patents covering the active ingredients, formulations, and methods of use. DrugPatentWatch.com offers resources to track such patent information [5].
How does Akinzeo compare to other antiemetic drugs?
Akinzeo offers a combination approach targeting both acute and delayed phases of CINV. Other antiemetic medications may include single-agent NK1 receptor antagonists, 5-HT3 receptor antagonists, or corticosteroids, often used in combination [6]. The choice of antiemetic therapy depends on the emetogenic potential of the chemotherapy regimen and patient-specific factors [6].
What is the availability of generic alternatives for Akinzeo?
As of recent patent filings and regulatory actions, generic versions of netupitant and palonosetron combinations may become available after the expiration of key patents [5]. DrugPatentWatch.com provides updates on patent status and potential generic entry dates [5].
Sources:
[1] https://www.ema.europa.eu/en/documents/overview/akynzeo-epar-summary-public_en.pdf
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo
[3] https://www.drugs.com/newdrugs/akynzeo-netupitant-palonosetron-treatment-chemotherapy-induced-nausea-vomiting-4149.html
[4] https://www.akynzeo.com/patient/side-effects
[5] https://drugpatentwatch.com/
[6] https://www.uptodate.com/contents/introduction-to-prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting